Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
Abstract Introduction For early detection of Alzheimer's disease (AD), the field needs biomarkers that can be used to detect disease status with high sensitivity and specificity. Apolipoprotein J (ApoJ, also known as clusterin) has long been associated with AD pathogenesis through various pathw...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| Subjects: | |
| Online Access: | https://doi.org/10.1016/j.dadm.2015.12.001 |
| _version_ | 1819103575000743936 |
|---|---|
| author | Veer Bala Gupta James D. Doecke Eugene Hone Steve Pedrini Simon M. Laws Madhav Thambisetty Ashley I. Bush Christopher C. Rowe Victor L. Villemagne David Ames Colin L. Masters Stuart Lance Macaulay Alan Rembach Stephanie R. Rainey‐Smith Ralph N. Martins AIBL Research Group |
| author_facet | Veer Bala Gupta James D. Doecke Eugene Hone Steve Pedrini Simon M. Laws Madhav Thambisetty Ashley I. Bush Christopher C. Rowe Victor L. Villemagne David Ames Colin L. Masters Stuart Lance Macaulay Alan Rembach Stephanie R. Rainey‐Smith Ralph N. Martins AIBL Research Group |
| author_sort | Veer Bala Gupta |
| collection | DOAJ |
| description | Abstract Introduction For early detection of Alzheimer's disease (AD), the field needs biomarkers that can be used to detect disease status with high sensitivity and specificity. Apolipoprotein J (ApoJ, also known as clusterin) has long been associated with AD pathogenesis through various pathways. The aim of this study was to investigate the potential of plasma apoJ as a blood biomarker for AD. Methods Using the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, the present study assayed plasma apoJ levels over baseline and 18 months in 833 individuals. Plasma ApoJ levels were analyzed with respect to clinical classification, age, gender, apolipoprotein E (APOE) ε4 allele status, mini‐mental state examination score, plasma amyloid beta (Aβ), neocortical Aβ burden (as measured by Pittsburgh compound B‐positron emission tomography), and total adjusted hippocampus volume. Results ApoJ was significantly higher in both mild cognitive impairment (MCI) and AD groups as compared with healthy controls (HC; P < .0001). ApoJ significantly correlated with both “standardized uptake value ratio” (SUVR) and hippocampus volume and weakly correlated with the plasma Aβ1–42/Aβ1–40 ratio. Plasma apoJ predicted both MCI and AD from HC with greater than 80% accuracy for AD and greater than 75% accuracy for MCI at both baseline and 18‐month time points. Discussion Mean apoJ levels were significantly higher in both MCI and AD groups. ApoJ was able to differentiate between HC with high SUVR and HC with low SUVR via APOE ε4 allele status, indicating that it may be included in a biomarker panel to identify AD before the onset of clinical symptoms. |
| first_indexed | 2024-12-22T01:52:38Z |
| format | Article |
| id | doaj.art-e67ea23dc1304ec49222744d11085b49 |
| institution | Directory Open Access Journal |
| issn | 2352-8729 |
| language | English |
| last_indexed | 2024-12-22T01:52:38Z |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| spelling | doaj.art-e67ea23dc1304ec49222744d11085b492022-12-21T18:42:53ZengWileyAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring2352-87292016-01-0131182610.1016/j.dadm.2015.12.001Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of agingVeer Bala Gupta0James D. Doecke1Eugene Hone2Steve Pedrini3Simon M. Laws4Madhav Thambisetty5Ashley I. Bush6Christopher C. Rowe7Victor L. Villemagne8David Ames9Colin L. Masters10Stuart Lance Macaulay11Alan Rembach12Stephanie R. Rainey‐Smith13Ralph N. Martins14AIBL Research Group15School of Medical Sciences, Edith Cowan UniversityJoondalupWAAustraliaCSIRO Health and BiosecurityBrisbaneAustraliaSchool of Medical Sciences, Edith Cowan UniversityJoondalupWAAustraliaSchool of Medical Sciences, Edith Cowan UniversityJoondalupWAAustraliaSchool of Medical Sciences, Edith Cowan UniversityJoondalupWAAustraliaUnit of Clinical and Translational Neuroscience Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of HealthBaltimoreMDUSACooperative Research Centre for Mental HealthMelbourneAustraliaDepartment of Nuclear Medicine and Centre for PETAustin HealthHeidelbergAustraliaDepartment of Nuclear Medicine and Centre for PETAustin HealthHeidelbergAustraliaNational Ageing Research InstituteParkvilleAustraliaOxidation Biology UnitThe Florey Institute, The University of MelbourneMelbourneAustraliaCSIRO Food and Nutrition FlagshipParkvilleAustraliaOxidation Biology UnitThe Florey Institute, The University of MelbourneMelbourneAustraliaSchool of Medical Sciences, Edith Cowan UniversityJoondalupWAAustraliaSchool of Medical Sciences, Edith Cowan UniversityJoondalupWAAustraliaSchool of Medical Sciences, Edith Cowan UniversityJoondalupWAAustraliaAbstract Introduction For early detection of Alzheimer's disease (AD), the field needs biomarkers that can be used to detect disease status with high sensitivity and specificity. Apolipoprotein J (ApoJ, also known as clusterin) has long been associated with AD pathogenesis through various pathways. The aim of this study was to investigate the potential of plasma apoJ as a blood biomarker for AD. Methods Using the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, the present study assayed plasma apoJ levels over baseline and 18 months in 833 individuals. Plasma ApoJ levels were analyzed with respect to clinical classification, age, gender, apolipoprotein E (APOE) ε4 allele status, mini‐mental state examination score, plasma amyloid beta (Aβ), neocortical Aβ burden (as measured by Pittsburgh compound B‐positron emission tomography), and total adjusted hippocampus volume. Results ApoJ was significantly higher in both mild cognitive impairment (MCI) and AD groups as compared with healthy controls (HC; P < .0001). ApoJ significantly correlated with both “standardized uptake value ratio” (SUVR) and hippocampus volume and weakly correlated with the plasma Aβ1–42/Aβ1–40 ratio. Plasma apoJ predicted both MCI and AD from HC with greater than 80% accuracy for AD and greater than 75% accuracy for MCI at both baseline and 18‐month time points. Discussion Mean apoJ levels were significantly higher in both MCI and AD groups. ApoJ was able to differentiate between HC with high SUVR and HC with low SUVR via APOE ε4 allele status, indicating that it may be included in a biomarker panel to identify AD before the onset of clinical symptoms.https://doi.org/10.1016/j.dadm.2015.12.001BiomarkersApolipoprotein JPlasmaBrain amyloid betaHippocampus volume |
| spellingShingle | Veer Bala Gupta James D. Doecke Eugene Hone Steve Pedrini Simon M. Laws Madhav Thambisetty Ashley I. Bush Christopher C. Rowe Victor L. Villemagne David Ames Colin L. Masters Stuart Lance Macaulay Alan Rembach Stephanie R. Rainey‐Smith Ralph N. Martins AIBL Research Group Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring Biomarkers Apolipoprotein J Plasma Brain amyloid beta Hippocampus volume |
| title | Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging |
| title_full | Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging |
| title_fullStr | Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging |
| title_full_unstemmed | Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging |
| title_short | Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging |
| title_sort | plasma apolipoprotein j as a potential biomarker for alzheimer s disease australian imaging biomarkers and lifestyle study of aging |
| topic | Biomarkers Apolipoprotein J Plasma Brain amyloid beta Hippocampus volume |
| url | https://doi.org/10.1016/j.dadm.2015.12.001 |
| work_keys_str_mv | AT veerbalagupta plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT jamesddoecke plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT eugenehone plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT stevepedrini plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT simonmlaws plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT madhavthambisetty plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT ashleyibush plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT christophercrowe plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT victorlvillemagne plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT davidames plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT colinlmasters plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT stuartlancemacaulay plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT alanrembach plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT stephanierraineysmith plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT ralphnmartins plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging AT aiblresearchgroup plasmaapolipoproteinjasapotentialbiomarkerforalzheimersdiseaseaustralianimagingbiomarkersandlifestylestudyofaging |